Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. - Wikidata - awgldk - TriplyDB

Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

http://www.wikidata.org/entity/Q36498966

about

IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia Roles of bioactive sphingolipids in cancer biology and therapeutics Ceramide mediates FasL-induced caspase 8 activation in colon carcinoma cells to enhance FasL-induced cytotoxicity by tumor-specific cytotoxic T lymphocytes Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer.The pleiotropic roles of sphingolipid signaling in autophagy Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity Interdiction of sphingolipid metabolism to improve standard cancer therapies.LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria.C16-Ceramide Analog Combined with Pc 4 Photodynamic Therapy Evokes Enhanced Total Ceramide Accumulation, Promotion of DEVDase Activation in the Absence of Apoptosis, and Augmented Overall Cell Killing Combining anticancer agents photodynamic therapy and LCL85 leads to distinct changes in the sphingolipid profile, autophagy, caspase-3 activation in the absence of cell death, and long-term sensitization Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs.Enhanced tumor cures after Foscan photodynamic therapy combined with the ceramide analog LCL29. Evidence from mouse squamous cell carcinomas for sphingolipids as biomarkers of treatment response.Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B Novel analogs of D-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents.Acid ceramidase as a therapeutic target in metastatic prostate cancer.Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas.Cationic ceramides and analogues, LCL30 and LCL85, as adjuvants to photodynamic therapy of tumors.Molecular targeting of acid ceramidase: implications to cancer therapy.Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system.Novel chemotherapeutic drugs in sphingolipid cancer research.Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.The subcellular distribution of small molecules: from pharmacokinetics to synthetic biology Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.Fragment-Based Hologram QSAR Studies on a Series of 2,4-Dioxopyrimidine-1-Carboxamides As Highly Potent Inhibitors of Acid Ceramidase Synthetic, non-natural analogs of ceramide elevate cellular ceramide, inducing apoptotic death to prostate cancer cells and eradicating tumors in mice.Synthesis and bioevaluation of omega-N-amino analogs of B13.Potent inhibition of Acid ceramidase by novel B-13 analogues.The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells.Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression.Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.

P2860

Q24613953-5523F6E8-8575-4FC3-B9F4-EAE13073625C Q24657499-7149DF35-BF8D-4561-8F7F-F9EC6EEC7953 Q30357159-EA9CD2EB-1201-4709-81E0-08FCA589E1A3 Q33713317-3D44267C-99A2-42C3-8DE8-394A343B2746 Q33720239-C69808DA-DEF1-4FBC-98C9-344BCF16952B Q34321724-CAC89039-0F17-461C-B08E-FF5A17FAAD72 Q34373466-062E6C6A-C758-40D0-ADA0-01ACA499FA11 Q34453596-D2EFF89D-701A-4B65-9C7B-98F0BF51BC96 Q34736432-E63D705A-48C8-44AB-9777-02A99F921BAA Q35069168-7E107C44-FB9D-4A15-978A-38AEF20A4566 Q35645445-12433CA6-A354-41E1-B4B3-5D3642BB05CC Q35952297-D91140B7-FFBF-42E8-AAB6-07BEADBFEC5A Q36063053-9AAB7BBF-3792-4A5C-8A79-9C42638F1887 Q36526990-DE33A093-DED8-47E5-B2D9-C07884B8ED92 Q36754783-F4914254-432F-43BD-9081-2FD2C4B660C9 Q37123435-4D417F09-D09A-4E12-B551-5DDA0B77AE50 Q37163553-5936CBB3-5C7F-422C-AE6F-6EAF1DCD071D Q37239617-DB4B77DF-92DE-4433-805C-D75D230DBBD5 Q37486242-1D73D97D-B7C2-4C5C-B28F-B80CD5545F7D Q37502782-F2A88702-B161-46C8-BA6D-AF91049E8A63 Q37527497-BB5C32F2-2F42-4E77-8F7D-2270A214BA6A Q37721276-31C4BA8F-B4AE-4D57-A7DB-40056927AF5B Q37880161-D3CABAF5-1D6F-40FF-882C-860B4A1FF04E Q37909301-68E517B0-192E-4EE7-ABDB-CD095B9EB37F Q39088175-CF5268DB-34E8-4750-94C3-2A1A0D2996DB Q39614279-11E02EFF-F34C-4495-BBDB-F8984AA706F2 Q39762643-583DFFEE-1E5E-40BA-A827-C95D73CE5414 Q39883816-B29DB55A-F398-4C06-A291-D39E4D0E9287 Q41785136-21A6AD2D-3B98-4CFE-8D11-DFC96C67C253 Q43094374-A2B982FE-7575-48C3-B1AB-A10D79274CAF Q47643576-8F176B22-A98D-4E98-BBF8-60386CA749ED Q52726553-CF2A5971-C653-4A17-A168-DAA491E518EB

P2860

Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

http://www.wikidata.org/entity/Q36498966

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

@ast

Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

@en

type

label

Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

@ast

Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

@en

prefLabel

Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

@ast

Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

@en

P1433

Q36498966-3ACDA73E-92D3-450D-B21F-2816214DF791

P1476

Q36498966-3049289C-E983-4460-860F-0D82831F5B66

P2093

Q36498966-02D9DAC2-61DE-484C-88E7-DE0010FE0A6C

Q36498966-22C9ADA2-D07A-4926-8D8B-22FF62334BE5

Q36498966-237EA5BF-5B5C-4B0A-A7D6-E864060C03DA

Q36498966-3F559886-310A-4E47-B261-302E5C230301

Q36498966-66F9FDC2-6871-45C5-9F06-B73B098D03A3

Q36498966-94386DD7-C94E-4DB8-A035-FA6ECEBA44A8

Q36498966-C1BCC8C9-459D-41CF-BAC2-808C033E95D8

Q36498966-CB3D967B-A0E8-47EA-BEC6-54C00FF19A0A

Q36498966-F0B33084-F3E5-4345-A296-BA92EF603B88

Q36498966-F648F4A4-716E-47FB-B3EA-BFEAC8F8E876

P2860

Q36498966-043F1857-7404-4B96-BF2A-8300C0843573

Q36498966-0AA3EA4E-ECEC-4544-BD0E-78A3F9A4122A

Q36498966-0BCA2112-027F-4396-9F73-138FC0C632C9

Q36498966-1A9E760C-B939-4ABA-91F4-2E23222E9B40

Q36498966-1C901948-5F39-4546-988D-F056F8F9EAAA

Q36498966-22D5B9A3-6F0B-4B08-8AB1-14BE49091EF2

Q36498966-2792D230-2950-46A8-AC3F-24C93550AD1D

Q36498966-315424D4-0820-4E05-B6CD-3B75A477B782

Q36498966-3BC47F01-E57C-4E58-B12A-B5D4B3EB00DA

Q36498966-4304CF7C-640C-444F-8FD3-0AB888BB7620

P304

Q36498966-F6109FCE-6A23-43C4-AE71-7DE00A4F01CE

P31

Q36498966-C670C890-04DC-49F1-920A-FEC776EA938F

P356

Q36498966-1F5B1349-6EE5-45D7-B226-AD6C0C7C4542

P407

Q36498966-A1C627FA-9257-41A3-9227-7142DA0E1D7D

P433

Q36498966-8D85545B-9C2E-4E94-BBBD-5988E1EB7106

P478

Q36498966-234B8A5A-DC62-4E02-AD9F-CCE63B85E4D0

P50

Q36498966-012F696D-136E-4250-B8A4-0DCD8C05969B

P577

Q36498966-0521DDA7-08CF-4DAE-B74F-D743FCED7D79

P5875

Q36498966-07EB77F5-3A0B-47B5-BD7F-0A5DB6427781

P698

Q36498966-96F7C0B6-B2D8-48C3-A3D6-E1154684E20F

P932

Q36498966-70731409-518E-4E3F-90FA-64167FB84373

P356

J.BMC.2007.08.032

P1433

Bioorganic & Medicinal Chemistry

P1476

Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

@en

P2093

AiPing Bai

http://www.w3.org/2001/XMLSchema#string

Alicja Bielawska

http://www.w3.org/2001/XMLSchema#string

Barbara Rembiesa

http://www.w3.org/2001/XMLSchema#string

Jacek Bielawski

http://www.w3.org/2001/XMLSchema#string

James S Norris

http://www.w3.org/2001/XMLSchema#string

Jason Pierce

http://www.w3.org/2001/XMLSchema#string

Nalini Mayroo

http://www.w3.org/2001/XMLSchema#string

Saeed Elojeimy

http://www.w3.org/2001/XMLSchema#string

Xiang Liu

http://www.w3.org/2001/XMLSchema#string

Zdzislaw M Szulc

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular machinery for non-vesicular trafficking of ceramide

The complex life of simple sphingolipids

A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death

The structural requirements for ceramide activation of serine-threonine protein phosphatases

Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells

Design, synthesis and activity as acid ceramidase inhibitors of 2-oxooctanoyl and N-oleoylethanolamine analogues

Tailoring structure-function and targeting properties of ceramides by site-specific cationization.

Fluorescence properties and staining behavior of monodansylpentane, a structural homologue of the lysosomotropic agent monodansylcadaverine.

Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer.

Golgi fragmentation is associated with ceramide-induced cellular effects.

P304

1032-1045

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BMC.2007.08.032

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5962327

http://www.w3.org/2001/XMLSchema#string

P698

17881234

http://www.w3.org/2001/XMLSchema#string

P932

2268750

http://www.w3.org/2001/XMLSchema#string